---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-027858"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:15:07.780414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic partners with MGH VIC and Voltron for vaccine antigens; part of $5.88M DoD award

## Summary
- Dyadic’s C1 platform to express vaccine antigens for influenza A and other infectious diseases.
- Collaboration stems from a $5.88M DoD award to VIC for Self-Assembling Vaccine platform.
- Aims to enable scalable, rapid vaccine production in 100 days or less at flexible scales.
- Potential commercial revenue for Dyadic if products are brought to market.
- Partners include Vaccine and Immunotherapy Center at MGH and Voltron Therapeutics.

## SEC filing metadata
- accession: 0001437749-23-027858
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774923027858/0001437749-23-027858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774923027858/dyai20231004_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-027858
- JSON: https://secwatch.observer/filing/0001437749-23-027858.json
- Plain text: https://secwatch.observer/filing/0001437749-23-027858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.